YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
May 14, 16:00
5195.85
-106.15 (-2%)
VOLUME 233,088
LIVE
NSE
May 14, 15:59
5196.85
-104.6 (-1.97%)
VOLUME 2,977,011
News on Dr Reddys Laboratories
Select Year: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Dr Reddy's launches oral suspension drug in the US market

12.41 pm | 27 Dec 2018 |  Source: PTI

The newly launched product is in the strengths of 0.8 g and 2.4 g packets, and is a therapeutic equivalent generic version of Renvela (sevelamer carbo...

Dr Reddy's launches anti-coagulant drug in US market

11.41 am | 24 Dec 2018 |  Source: PTI

The product is a therapeutic equivalent to generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules, the company said in a BSE...

Buy Dr Reddy’s Laboratories, target Rs 2900: Aditya Agarwal

10.54 am | 30 Nov 2018 |  Source: Moneycontrol.com

We recommend traders to buy this stock in the range of Rs 2650 to 2625 with a price target of Rs 2900 and a stop loss placed below Rs 2520, says Adity...

Dr Reddy's launches blood pressure drug in US

11.19 am | 28 Nov 2018 |  Source: PTI

Dr Reddy's Laboratories Ltd launched Chlorthalidone tablets USP in the strengths of 25 mg and 50 mg, a therapeutic equivalent generic version of H...

US appeals court allows Dr Reddy's Labs to sell generic Suboxone

8.57 am | 21 Nov 2018 |  Source: Moneycontrol.com

Dr Reddy's had booked sales of around $10-15 million days after its launch before it was stayed by the court....

Follow-on audit of Duvvada unit by German authority complete: Dr Reddy's

2.52 pm | 12 Nov 2018 |  Source: PTI

"On November 9, 2018, the Regulatory Authority of Germany (Regierung von Oberbayem) concluded the follow-on audit of our formulations manufacturing fa...

US pricing pressure shows signs of easing as drug makers prune loss-making portfolios

5.14 pm | 09 Nov 2018 |  Source: Moneycontrol.com

To beat the pricing pressure and maintain profit margins, large generic drug makers have responded by slashing their generic pipelines and ANDA filing...

Buy Dr Reddy’s Laboratories; target of Rs 2700: ICICI Direct

2.12 pm | 31 Oct 2018 |  Source: Moneycontrol.com

ICICI Direct is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 2700 in its research report dat...

Dr Reddy's Labs announces generic version of Straterra in US market

1.52 pm | 31 Oct 2018 |  Source: PTI

The Hyderabad-based company has received the approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equiva...

Dr Reddy's gets 8 observations from USFDA for Duvvada plant

9.57 pm | 30 Oct 2018 |  Source: PTI

As per the USFDA, a Form 483 is issued to a firm's management at the conclusion of an inspection when investigator has observed any conditions tha...

Indian API makers expect rise in order inflows amid price hikes, supply disruption in China

6.35 pm | 30 Oct 2018 |  Source: Moneycontrol.com

Moneycontrol reported in August that some drug makers are working towards producing APIs and key starting materials in house, while others have starte...

Dr Reddy’s Q2 review: Brokerages term results to be in line with estimates; Citi rises target to Rs 2,680

2.35 pm | 29 Oct 2018 |  Source: Moneycontrol.com

The pharma major reported a rise of 77 percent (year-on-year) in its net profit at Rs 503.8 crore. The company had reported a profit of Rs 284.9 crore...

Dr Reddy’s says focusing on resolving regulatory issues, cost optimisation

9.17 pm | 26 Oct 2018 |  Source: Moneycontrol.com

“Looking ahead, our priority will be to resolve pending regulatory issues, and continue to work on execution and cost structures that will enable af...

Dr Reddy’s posts 77% rise in Q2 net profit at Rs 503.8 crore; posts healthy operational show

3.17 pm | 26 Oct 2018 |  Source: Moneycontrol.com

The revenue rose to Rs 3,797.8 crore against Rs 3,546 crore that the company posted during the corresponding quarter of last year. This implies a rise...

Dr Reddy’s Q2 preview: Brokerages expect subdued show, profit likely around Rs 330-370 cr

9.12 am | 26 Oct 2018 |  Source: Moneycontrol.com

The effect of Suboxone based on US court order is likely to weigh as well....

Re-audit of Duvvada unit: Why an all clear holds importance for Dr Reddy’s

3.41 pm | 24 Oct 2018 |  Source: Moneycontrol.com

A portion of complex abbreviated new drug applications is filed from this facility...

Will Dr Reddy's biosimilar programme for developed markets see traction?

9.51 am | 19 Oct 2018 |  Source: Moneycontrol.com

The drug maker's partner Fresenius Kabi has completed clinical trial for Pegfilgrastim and announced that the drug has met primary end point in tw...

Dr. Reddy’s Labs Q2 PAT seen up 32% YoY to Rs. 380 cr: HDFC Securities

5.40 pm | 17 Oct 2018 |  Source: Moneycontrol.com

Net Sales are expected to increase by 10.8 percent Y-o-Y (up 5.6 percent Q-o-Q) to Rs. 3,930 crore, according to HDFC Securities....

Dr. Reddy’s Lab Q2 PAT seen up 20.2% YoY to Rs. 356.1 cr: Sharekhan

11.23 am | 17 Oct 2018 |  Source: Moneycontrol.com

Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 3,750 crore, according to Sharekhan....

1 2 3 4 5 6
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.